ClinicalXchange Internal Medicine podcasts: Recent Episodes
Clinical Care Solutions
Welcome to the Clinical Care Solutions Internal Medicine podcast channel. Our podcast shows give you quick access to important content when you need it - at home, at your desk, or on the go.
How common is treatment inertia in the treatment of adult patients with T2D and what can be done about it? Join a multidisciplinary panel including Jim Gavin, MD, PhD; Steve Vacalis, DO; and Jodi Strong, DNP, CDE, BC-ADM, CPT as they discuss and share their insights on the issues surrounding therapeutic inertia. They will also evaluate when to use a GLP-1 RA, and a clinical trial comparing the efficacy and safety of a GLP-1 RA versus a DPP-4i.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia
Jodi Strong, DNP, CDCES, BC-ADM, CPT
Aspirus Medical Group
Stevens Point, Wisconsin
Steve Vacalis, DO
Senior Lead Physician
CaroMont Family Medicine, CaroMont Regional Medical Center
Gastonia, North Carolina
What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia
Jeff Unger, MD, FAAFP, FACE
Diplomate, American Board of Family Practice
Assistant Clinical Professor of Family Medicine, UC Riverside School of Medicine
Riverside, California
Director, Unger Concierge Primary Care Medical Group
Rancho Cucamonga, California
Curtis L. Triplitt, PharmD, CDCES, FADCES
Clinical Associate Professor of Medicine Division of Diabetes
University of Texas Health at San Antonio
Texas Diabetes Institute, part of the University Health System
San Antonio, Texas
Faculty:
Neil Skolnik, MD
Family Physician & Professor of Family & Community Medicine
Sidney Kimmel Medical College,
Thomas Jefferson University
Corinne Young, FNP-C, FCCP
Nurse Practitioner
Pulmonary, Critical Care, and Sleep Medicine
Colorado Springs Pulmonary Consultants, PC
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia
Robert Busch, MD
Director of Clinical Research
Albany Med Faculty Practice, Community Endocrine Group
Albany, New York
Pablo F. Mora, MD, FACE, MSc, CDCES
Endocrinologist, North Texas Diabetes & Endocrinology
Clinical Professor, Division of Endocrinology at University of Texas Southwestern Medical Center
Dallas, Texas
Should we be thinking differently about type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson (primary care provider), Ms Lucia Novak (Nurse Practitioner), and Dr Joshua Stolker (cardiologist) as they talk about ways to think differently about type 2 diabetes and consider factors in addition to A1C such as comorbidities, recommendations on managing patients with T2D from national endocrinology and cardiology societies, and how the cardiology community can work with the diabetology community to provide the best care for patients with T2D.
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
Faculty Presenters:
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee
Lucia M. Novak, MSN, ANP-BC, BC-ADM
President and Owner
Diabetes Consulting Services
North Bethesda, Maryland
Co-Executive Director
Capital Health & Metabolic Center of Capital Diabetes & Endocrine Associates
Camp Springs and Silver Spring, Maryland
Joshua M. Stolker, MD
STEMI Director
Mercy Heart and Vascular
Washington, Missouri
Adjunct Associate Professor
Saint Louis University
St Louis, Missouri
What are the prevalence, increased risk, and impact of cardiovascular disease (CVD) among patients with type 2 diabetes (T2D)? Join experts: Drs John Anderson (primary care physician), Pam Taub (cardiologist), and Mark Greathouse (cardiologist) as they review the relationship between T2D and CVD, including how T2D exacerbates CVD and the risk from CVD, and what the national medical associations recommend for patients with T2D and CVD.
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
Faculty Presenters:
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee
Pam Taub, MD, FACC
Cardiologist and Professor of Medicine
Director, Cardiac Rehabilitation and Wellness Center
UC San Diego Health
San Diego, California
Mark Greathouse, MD
Senior Clinical Cardiologist
St Clair Health
Pittsburgh, Pennsylvania
Episode #5: What is the impact of insufficient GLP-1 activity in type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson, Dr Javier Morales, and Dr Richard Pratley as they review the role of GLP-1 in glucose regulation, consider the impact of insufficient GLP-1 activity on pancreatic beta cells in patients with T2D, and discuss possibilities to overcome insufficient GLP-1 activity in patients with T2D.
This podcast is sponsored by Novo Nordisk and is intended for Healthcare Practitioners.
Faculty Presenters:
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee
Javier Morales, MD, FACP, FACE
Internal Medicine, Diabetes, and Primary Care
Associate Clinical Professor
Hofstra/Northwell School of Medicine at the Donald and Barbara Zucker School of Medicine
Long Island, New York
Richard E. Pratley, MD
Internal Medicine and Diabetes
AdventHealth Diabetes Institute
Orlando, Florida
Rita F. Redberg MD, MSc, FACC
Professor of Medicine
Araxe Vilensky Endowed Chair in Cardiology
Faculty, Philip R Lee Institute for Health Policy Studies
Editor, JAMA Internal Medicine
Director, Inquiry Program
UCSF Division of Cardiology
San Francisco, CA
Nearly one-fourth of American adults take lipid-lowering statin medications. However, more people may be eligible. Statin Wars continue to be underway over whether statins should be used not just for the secondary prevention of cardiovascular disease (CVD), but also primary prevention.
Event Sponsors
This event is sponsored by Clinical Care Solutions and is not sponsored by industry.
What is the role of endogenous GLP-1 in the pathophysiology of T2D? Join multidisciplinary experts in T2D: Dr John Anderson, Dr Vivian Fonseca, and Dr Jim Gavin as they discuss the fascinating history of GLP-1 discovery and the role of endogenous GLP-1 in the pathophysiology of T2D.
This podcast is sponsored by Novo Nordisk and is intended for Healthcare Practitioners.
Faculty Presenters:
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee
Vivian A. Fonseca, MD, FRCP
Professor of Medicine, Assistant Dean for Research
Tulane University
New Orleans, Louisiana
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia
What do you know about the role of beta-cell dysfunction in the pathophysiology of type 2 diabetes (T2D)? Join primary care experts in T2D: Dr. John Anderson, Dr. Stephen Brunton and Dr. James LaSalle as we discuss the beta-cell function and its critical role in T2D pathogenesis, what clinicians know or should know about it and how it is measured in the clinic, and how our current knowledge of beta-cell function in T2D may affect future research on T2D treatment.
This podcast is sponsored by Novo Nordisk and is intended for clinicians. The opinions expressed are those of the speakers and not Novo Nordisk.
Faculty Presenters:
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee
Stephen Brunton, MD, FAAFP
Executive Director
Primary Care Metabolic Group
Winnsboro, South Carolina
James LaSalle, DO, FAAFP
Medical Arts of Excelsior Springs, Inc.
Excelsior Springs, Missouri
Episode #2:
What is the burden of the type 2 diabetes (T2D) epidemic? Join experts in T2D: Dr. John Anderson (primary care provider), Dr. Susan Cornell (clinical pharmacist and certified diabetes care and education specialist) and Dr. Doron Schneider (primary care provider) as they discuss the enormous physical, emotional, psychological and economic burden of T2D and its comorbidities on the US healthcare system and on their patients and what they, as clinicians need to do to ease this burden.
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
Faculty Presenters:
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee
Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES
Associate Director of Experiential Education
Professor of Pharmacy Practice
Midwestern University Chicago College of Pharmacy
Downers Grove, Illinois
Doron Schneider, MD, MBA, FACP
Vice President, Population Health Services
Tandigm Health
West Conshohocken, Pennsylvania
What is the impact of COVID-19 on adult patients with type 2 diabetes (T2D) and how do we navigate healthcare when an epidemic and pandemic seemingly join forces to further exacerbate patient outcomes? Join experts in T2D: Dr. John Anderson (primary care provider), Dr. Eden Miller (primary care provider), and Dr. Serge Jabbour (endocrinologist) for an in-depth discussion on how COVID-19 impacts patients with T2D and what you can do to help your patients as new information is discovered during this evolving landscape.
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
Faculty Presenters:
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee
Eden Miller, DO, FOMA
Diabetes Care, Obesity, Family Medicine
Founder, Diabetes and Obesity Care, LLC
Bend, Oregon
Serge A. Jabbour, MD, FACP, FAC
Diabetes, Clinical Trials of Diabetes Treatments, Obesity
Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolic Diseases
Director, Jefferson Diabetes Center, Division of Endocrinology, Diabetes and Metabolic Diseases
Sidney Kimmel Medical College/Thomas Jefferson University
Philadelphia, PA
Presenter:
Michael J. Bloch MD, FACP, FASH, FNLA, FSVM
Associate Professor, University of Nevada School of Medicine
Medical Director, Renown Vascular Care, Renown Institute for Heart and Vascular Health
President, Blue Spruce Medical Consultants, PLLC
Reno, Nevada
Hypertension is commonly seen in primary care practice settings. It requires up-to-date evidence-based management to optimize clinical outcomes for patients. This activity presents multiple clinical pearls on this topic through a Q&A format, highlighting common clinical challenges that primary care physicians face when treating patients with hypertension. Using recent data and existing guidelines, recommendations for management will be reviewed starting from diagnosis through initial treatment selection.
Follow along with the slideset located here:
https://bit.ly/3AD5ln9
Presenter:
Javed Butler MD, MPH, MBA
Professor and Chairman
Department of Medicine
University of Mississippi
Jackson, Mississippi
Heart Failure is a serious health concern amongst older adults, afflicting over 6 million Americans, the majority of whom are 65 years of age or older. It is the leading cause of hospitalization, morbidity, and mortality in this population. It is more challenging to diagnose and manage HF in older patients due to multiple factors including multimorbidity, polypharmacy, cognitive impairment, and frailty. Furthermore, clinicians struggle to remain up-to-date on key clinical trial data and recent guidelines on developing individualized treatment plans for patients. To improve outcomes for patients with HF, clinicians must be adept at recognizing its common signs or symptoms, conducting a thorough diagnostic evaluation, and developing a treatment plan that addresses the multiple challenges and complexities that this patient population faces. Here, we cover these key principles in a short, case-based teaching module.
Follow along with the slideset located here:
https://bit.ly/3EGHtBx
Presenter:
Samuel Louie, MD
Professor
Director, UC Davis Asthma Network (UCAN)
Director, Reversible Obstructive Airway Disease (ROAD) Center
Sacramento, CA
In this brief program, expert faculty will discuss the application of new options to improve outcomes for those with moderate to severe asthma. First, the faculty will describe the features of uncontrolled asthma and asthma phenotypes. Next, case studies will be used to aid in identification of patients with severe asthma for whom use of add-on biologic therapy may be appropriate based on efficacy, safety, and disease- and patient-specific factors. Finally, the faculty will share approaches to shared decision-making with patients that result in written action plans and strategies for addressing adherence and multidisciplinary management of asthma and its comorbidities.
Follow along with the slideset located here:
https://bit.ly/3Av1OXR